BioWorld

Jan. 16, 2004

Genentech Beats 4Q Estimates, Files To Expand Nutropin Label

Genentech Inc. released year-end and quarterly earnings that beat consensus estimates, simultaneously disclosing its application for an expanded indication of one of its growth hormone products. (BioWorld Today) Read More

JPMorgan, Bank One Merger Puts 'Uncertainty' On Biotech

TargeGen's Series B Brings In $30M For AMI, Cancer Programs

NovaScreen Signs Biodefense Contract On Immune Boosters

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Feb. 10, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026